Safety, Immunogenicity of a Novel HPBCD-Adjuvanted Influenza Vaccine

Posted by

A novel quadrivalent seasonal influenza vaccine (FluCyd-vac) adjuvanted with hydroxypropropyl-b-cyclodextrin (HP-β-CD) was found to be safe and immunogenic despite containing 40% less hemagglutinin (HA) antigens than that of a standard influenza vaccine, according to results of a phase 1 clinical trial published in Vaccine. The FluCyd-vac contained 9 mg of HA plus 20% weight per volume of HPBCD, and the standard vaccine (Flu-vac) contained 15 mg of HA.

Among 36 healthy volunteers enrolled in the study (FluCyD-vac, n = 24; Flu-vac, n = 12), FluCyD-vac was well tolerated. Most of the solicited adverse events were mild local skin reactions at the injection site. No serious adverse events were reported in either group. The activation of tumor necrosis factor-a and subsequent production of CD4+ T cells when HP-b-CyD is co-administered with HA antigens “could overcome the disadvantage of the relatively weak immunogenicity of the HA split vaccine,” the researchers concluded.

Watanabe A, Nishida S, Burcu T, et al. Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl-β-cyclodextrin: a phase 1 clinical trial. Vaccine. 2022;40(31):4150-4159. doi:10.1016/j.vaccine.2022.05.060

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.